Esophageal Cancer Clinical Trial
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies
This is a Phase 1/1b, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB308 in combination with zimberelimab (AB122) in participants with advanced malignancies.
Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
Male or female participants ≥ 18 years of age (or age ≥ regionally approved age of consent for participation in investigational clinical studies) at the time of signing the informed consent.
Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
Adequate organ and marrow function
History of trauma or major surgery within 28 days prior to the first dose of study treatment.
Prior treatment with an anti-TIGIT antibody.
Any active or prior autoimmune disease that required treatment within 3 years of the first dose of study treatment.
Prior chemotherapy, targeted small-molecule therapy, immunotherapy, or biologic agents, or use of other investigational drugs within 28 days before first dose of study treatment.
Discontinued prior immunotherapy for immune related adverse events with a high severity.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 20 Locations for this study
Phoenix Arizona, 85054, United States
Los Angeles California, 90095, United States
Aurora Colorado, 80045, United States
Jacksonville Florida, 32224, United States
Orlando Florida, 43210, United States
Augusta Georgia, 30909, United States
Goshen Indiana, 46526, United States
Iowa City Iowa, 52242, United States
Louisville Kentucky, 40202, United States
Novi Michigan, 48377, United States
Rochester Minnesota, 55905, United States
New York New York, 10032, United States
Canton Ohio, 44718, United States
Columbus Ohio, 43210, United States
Oklahoma City Oklahoma, 73104, United States
Pittsburgh Pennsylvania, 15240, United States
Nashville Tennessee, 37205, United States
San Antonio Texas, 78229, United States
West Valley City Utah, 84119, United States
Fairfax Virginia, 22033, United States
Madison Wisconsin, 53792, United States
Kraków , , Poland
Lubin , , Poland
Olsztyn , , Poland
Poznań , , Poland
Warszawa , , Poland
Barcelona , , Spain
Madrid , , Spain
Madrid , , Spain
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.